2026-2032 年牛血浆衍生物市场（依衍生物类型、应用及地区划分）

2026-2032年牛血浆衍生物市场评估

血浆衍生物在疫苗和治疗产品中的使用日益增多，推动了牛血浆衍生物的采用。富含蛋白质的营养补充品越来越受欢迎，尤其是在体育和健康产业，推动市场规模在 2024 年超过 19.6 亿美元，到 2032 年达到约 30.6 亿美元的估值。

此外，人们对动物健康和营养的认识不断提高，也推动了兽药对血浆衍生物的需求，从而促进了牛血浆衍生物的采用。发展中地区的经济成长和肉类消费量的增加，使得该市场在2026年至2032年间的复合年增长率达到5.70%。

牛血浆衍生物市场定义/概述

牛血浆衍生物是从牛血浆（血液去除细胞后剩余的液体部分）中提取的成分。这些衍生物含有多种蛋白质，包括免疫球蛋白、白蛋白和纤维蛋白原，并经过加工以确保安全性和有效性。由于其丰富的营养和生物学特性，它们在兽医和人类医学中都发挥着重要作用。

牛血浆衍生物在各领域有广泛的应用。在医疗领域，由于其高蛋白质含量和生物活性，它们被用于治疗免疫力缺乏、创伤治疗和外科手术。在食品工业中，它们可用作膳食补充剂和蛋白粉、运动营养配方等产品中的功能性成分。此外，在农业领域，血浆衍生物可用于牲畜饲料，以促进牲畜生长和增强免疫力。

动物用药品产业日益增长的需求将如何促进牛血浆衍生物的采用？

免疫力缺乏缺陷症和出血性疾病的日益流行，催生了对血浆疗法的巨大需求，成为牛血浆衍生物市场的主要驱动力。世界卫生组织 (WHO) 预计，2021 年至 2023 年间，全球原发性免疫力缺乏的盛行率将增加 28%，这必然要求增加血浆衍生物的产量。在关键进展方面，赛默飞世尔科技于 2024 年 1 月宣布扩建其在北美的牛血浆采集设施，而默克则透过引进新的血浆分馏技术，提高了生产效率和产品品质。

牛血浆衍生物在细胞培养基和生物技术研究中的应用日益广泛，是另一个关键的市场驱动力。根据美国国立卫生研究院的报告，到2023年，使用牛血浆成分进行细胞培养研究的支出将增加35%，达到8.92亿美元。这一趋势促使业界采取了重大倡议，例如SAFC Biosciences于2024年3月推出了一款牛血浆的先进细胞培养补充剂，GE Healthcare Life Sciences则扩大了其用于生物製药生产的牛生长因子产品组合。

动物用药品产业需求的成长是第三个关键驱动因素，这得益于动物保健和营养领域应用的不断增长。美国农业部记录到，2023年，动物用药品中牛血浆衍生物的使用量与前一年同期比较去年同期成长了42%。近期的发展包括：硕腾公司于2024年2月推出了一系列基于血浆的牲畜营养补充剂；勃林格殷格翰动物保健公司与一家领先的血浆采集公司建立了战略合作伙伴关係，从而加强了兽药生产的供应链。

疾病传播风险会限制牛血浆市场的成长吗？

牛血浆衍生物市场面临监管挑战，阻碍了其成长。围绕动物性产品的收集、加工和使用的严格监管通常需要大量的测试和合规措施。这会导致製造商成本增加，小型企业的市场准入受限，并可能影响整体市场扩张。

另一个主要限制因素是疾病传播的风险。对牛脑病变（BSE）等通用感染疾病的担忧，可能导致消费者对使用牛产品犹豫不决。这种风险需要严格的安全通讯协定，并可能使潜在买家望而却步，尤其是在食品安全意识日益增强的地区。

畜牧业的市场波动也会影响牛血浆衍生物的供应。由于疾病爆发、农业实践变化或市场需求等因素导致牛数量波动，可能导致原料供应不稳定。这种不稳定会扰乱生产计画，并导致价格波动，从而影响该行业企业的盈利。

目录

第一章 引言

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 市场概述

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章牛血浆衍生物市场（依衍生物类型）

• 概述
• 免疫球蛋白
• 纤维蛋白原
• 血清白蛋白
• 牛
• 凝血酶
• 新生牛血清

第六章牛血浆衍生物市场：依应用

• 概述
• 製药业
• 诊断产业
• 细胞培养/生物技术
• 研发业
• 食品工业
• 化妆品产业

第七章牛血浆衍生物市场：依地区

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争态势

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• CSL Limited
• Grifols SA
• Kedrion SpA
• Baxter International, Inc.
• Shire（now part of Takeda）
• Octapharma AG
• Biotest AG
• Fresenius Kabi AG
• LFB Group
• Sangamo Therapeutics, Inc.

第十章 附录

• 相关调查

Bovine Blood Plasma Derivatives Market Valuation - 2026-2032

Increased use of plasma derivatives in vaccines and therapeutic products is propelling the adoption of bovine blood plasma derivatives. The rising popularity of protein-rich nutritional supplements, particularly in sports and health industries is driving the market size to surpass USD 1.96 Billion valued in 2024 to reach a valuation of around USD 3.06 Billion by 2032.

In addition to this, increasing awareness of animal health and nutrition supports the demand for plasma derivatives in veterinary medicine is spurring up the adoption of bovine blood plasma derivatives. Growing economies and increasing meat consumption in developing regions is enabling the market to grow at a CAGR of 5.70% from 2026 to 2032.

Bovine Blood Plasma Derivatives Market: Definition/ Overview

Bovine blood plasma derivatives are components extracted from the blood plasma of cattle, which is the liquid part of blood that remains after cells have been removed. These derivatives include a variety of proteins, such as immunoglobulins, albumin, and fibrinogen, and are often processed to ensure safety and efficacy. They play a significant role in both veterinary and human medicine, owing to their rich nutritional and biological properties.

Bovine blood plasma derivatives have diverse applications across several fields. In the medical sector, they are used in the formulation of therapies for immune deficiencies, wound healing, and surgical applications, thanks to their high protein content and biological activity. In the food industry, they serve as nutritional supplements and functional ingredients in products like protein powders and sports nutrition formulations. Additionally, in agriculture, plasma derivatives are used in animal feed to enhance growth and immunity in livestock.

How will Rising Demand from the Veterinary Pharmaceutical Industry Increase Adoption of Bovine Blood Plasma Derivatives?

The increasing prevalence of immunodeficiency disorders and bleeding conditions has emerged as a primary driver for the bovine blood plasma derivatives market, creating substantial demand for plasma-based therapeutics. According to the World Health Organization, the global prevalence of primary immunodeficiency disorders increased by 28% between 2021 and 2023, necessitating increased production of plasma derivatives. In a significant development, Thermo Fisher Scientific announced in January 2024 its expansion of bovine plasma collection facilities across North America, while Merck's introduction of new plasma fractionation technologies has enhanced production efficiency and product quality.

The growing application of bovine plasma derivatives in cell culture media and biotechnology research represents another crucial market driver. The National Institutes of Health reported that research funding for cell culture studies utilizing bovine plasma components increased by 35% in 2023, reaching USD 892 Million. This trend has prompted major industry movements, with SAFC Biosciences launching an advanced cell culture supplement derived from bovine plasma in March 2024, while GE Healthcare Life Sciences expanded its portfolio of bovine-derived growth factors for biopharmaceutical production.

Rising demand from the veterinary pharmaceutical industry stands as the third significant driver, with increasing applications in animal healthcare and nutrition. The U.S. Department of Agriculture documented a 42% increase in the usage of bovine plasma derivatives in veterinary medicines during 2023 compared to the previous year. Recent developments include Zoetis's February 2024 announcement of a new line of plasma-based nutritional supplements for livestock, while Boehringer Ingelheim Animal Health's strategic partnership with a leading plasma collection company has strengthened its supply chain for veterinary therapeutics production.

Will Risk of Disease Transmission Restrain Bovine Blood Plasma Market Growth?

The bovine blood plasma derivatives market faces regulatory challenges that can hinder its growth. Strict regulations surrounding the collection, processing, and use of animal-derived products often require extensive testing and compliance measures. This can lead to increased costs for manufacturers and may limit market entry for smaller companies, impacting overall market expansion.

Another significant restraint is the risk of disease transmission. Concerns about zoonotic diseases, such as Bovine Spongiform Encephalopathy (BSE), can lead to consumer hesitance regarding the use of bovine-derived products. This risk necessitates rigorous safety protocols and can deter potential buyers, particularly in regions with heightened awareness of food safety issues.

Market fluctuations in the cattle industry can also affect the supply of bovine blood plasma derivatives. Variations in cattle populations due to factors like disease outbreaks, changing agricultural practices, or market demands can create instability in the availability of raw materials. This inconsistency can hinder production planning and lead to price volatility, impacting profitability for companies in the sector.

Category-Wise Acumens

Will Thrombin Segment Dominate in Bovine Blood Plasma Derivatives Market?

The thrombin segment maintains its dominant position in the bovine blood plasma derivatives market, driven by its crucial role in surgical procedures, wound healing, and diagnostic applications. According to the U.S. Food and Drug Administration, thrombin-based products accounted for 45% of all bovine plasma derivative approvals in 2023, highlighting its significant market share. This dominance has spurred major developments, with Pfizer announcing in February 2024 the expansion of its thrombin production facilities in Michigan, while Baxter International launched an advanced thrombin-based surgical sealant featuring enhanced stability and efficacy.

The increasing adoption of thrombin-based hemostatic agents in minimally invasive surgeries has further strengthened its market position. The European Medicines Agency reported a 38% increase in thrombin product usage across surgical procedures between 2022 and 2023. Recent developments include Johnson & Johnson's March 2024 introduction of a novel thrombin delivery system for laparoscopic surgeries, while Takeda Pharmaceutical's acquisition of a specialized plasma derivatives manufacturer has bolstered its thrombin product portfolio.

Which Factors Enhance the Use of Bovine Blood Plasma Derivatives in the Pharmaceutical Industry?

The pharmaceutical industry maintains its leadership in the bovine blood plasma derivatives market, driven by increasing applications in drug development, vaccine production, and therapeutic formulations. According to the U.S. Food and Drug Administration, pharmaceutical applications accounted for 62% of all approved bovine plasma derivative products in 2023, representing a significant market share. This dominance has prompted major developments, with GlaxoSmithKline announcing in January 2024 a $300 million investment in plasma processing facilities, while Novartis expanded its bovine-derived pharmaceutical portfolio through advanced fractionation technologies.

The industry's growth is further fueled by the rising demand for plasma-based vaccines and immunological products. The World Health Organization reported that pharmaceutical companies increased their bovine plasma derivative usage by 43% in 2023 for vaccine development and production. Recent developments include Merck's March 2024 launch of a new plasma-derived growth factor supplement for cell culture applications, while Pfizer's strategic partnership with a leading plasma collection network has strengthened its supply chain for pharmaceutical product development.

Country/Region-wise Acumens

Will Diversity And Vast Workforce in North America Drive Bovine Blood Plasma Derivatives Market Growth?

North America is known to embrace technological advancements leading to early adoption and widespread use of bovine blood plasma derivatives. This is likely to attract a mature ecosystem of established vendors, diverse solutions, and skilled professionals. The higher disposable income and knowledge regarding technological benefits in comparison to other regions is bolstering the application and willingness to invest in Bovine Blood Plasma Derivatives in the organizations located in North America.

Also, the diversity and vast workforce in North America in the prevalent and emerging organizations in industrialized countries like the U.S., Canada are necessitating advanced timekeeping solutions catering to various industries, employee types, and complex work arrangements.

Furthermore, the implementation of strict wage and hour laws along with a strong focus on workplace regulation is driving the demand for accurate and compliant timekeeping solutions to avoid penalties and legal issues. Introduction of well-developed internet infrastructure in tech-savvy environment create a fertile ground for cloud-based solutions and advanced features like biometrics and AI-powered analytics. These innovations are enabling North America dominate the Bovine Blood Plasma Derivatives market during the forecast period.

Will Increasing Research Activities Enhance Adoption of Bovine Blood Plasma Derivatives in Asia Pacific?

The bovine blood plasma derivatives market in Asia Pacific is experiencing remarkable growth, driven by expanding healthcare infrastructure, increasing research activities, and rising demand for plasma-based products across pharmaceutical and biotechnology sectors. According to China's National Medical Products Administration, the regional market for bovine plasma derivatives grew by 38% in 2023, reaching a value of USD 1.5 Billion. This growth trajectory has attracted significant investments, with Samsung Biologics announcing in February 2024 the establishment of a state-of-the-art plasma processing facility in South Korea, while Japan's Takeda Pharmaceutical expanded its presence through a strategic partnership with leading Chinese biotechnology firms.

The region's rapid advancement in biotechnology research and development is fueling market expansion. The Indian Council of Medical Research reported a 45% increase in research projects utilizing bovine plasma derivatives during 2023, with total funding reaching ₹850 crore (USD 103 Million). Recent developments include Thai-based Charoen Pokphand Group's March 2024 launch of Asia's largest bovine plasma collection network, while Singapore's Bio*One Capital invested USD 200 Million in developing advanced plasma fractionation technologies.

Competitive Landscape

The bovine blood plasma derivatives market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the bovine blood plasma derivatives market include:

• CSL Limited
• Grifols S.A.
• Kedrion S.p.A.
• Baxter International, Inc.
• Shire (now part of Takeda)
• Octapharma AG
• Biotest AG
• Fresenius Kabi AG
• LFB Group
• Sangamo Therapeutics, Inc.
• HemaCare Corporation
• Hemex Health
• HemaSource, Inc.
• Proliant Biologicals
• Thermo Fisher Scientific, Inc.
• American Blood Resources Association (ABRA)
• Bovine Blood Products Co.
• Centeon (a part of the LFB Group)
• PPL Therapeutics
• PlasmaLyte

Latest Developments

• In November 2023, Baxalta announced the expansion of its bovine blood plasma derivatives production facility to increase capacity and meet rising global demand for immunoglobulin therapies.
• In September 2023, Grifols launched a new line of bovine-derived albumin products aimed at enhancing patient outcomes in critical care settings, highlighting advancements in product purity and efficacy.

Bovine Blood Plasma Derivatives Market, By Category

• Derivatives Type:
• Immunoglobulin
• Fibrinogen
• Serum Albumin
• Fetal Bovine Serum
• Thrombin
• New Born Calf Serum
• Application:
• Pharmaceutical Industry
• Diagnostics Industry
• Cell Culture/Biotechnology
• Research and Development
• Food Industry
• Cosmetic Industry
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY DERIVATIVES TYPE

• 5.1 Overview
• 5.2 Immunoglobulin
• 5.3 Fibrinogen
• 5.4 Serum Albumin
• 5.5 Fetal Bovine Serum
• 5.6 Thrombin
• 5.7 New Born Calf Serum

6 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Pharmaceutical Industry
• 6.3 Diagnostics Industry
• 6.4 Cell Culture/ Biotechnology
• 6.5 Research and Development
• 6.6 Food Industry
• 6.7 Cosmetic Industry

7 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CSL Limited
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Grifols S.A.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Kedrion S.p.A.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Baxter International, Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Shire (now part of Takeda)
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Octapharma AG
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Biotest AG
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Fresenius Kabi AG
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 LFB Group
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Sangamo Therapeutics, Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research